Wedbush set a $79.00 target price on Aimmune Therapeutics (NASDAQ:AIMT) in a research note published on Thursday morning, TipRanks reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other research analysts have also recently weighed in on the company. ValuEngine raised Zillow Group from a hold rating to a buy rating in a research report on Thursday. BidaskClub raised Zillow Group from a buy rating to a strong-buy rating in a report on Tuesday, July 2nd. Credit Suisse Group lowered their price target on Athene from $67.00 to $57.00 and set an outperform rating on the stock in a report on Tuesday, May 21st. Cantor Fitzgerald reissued a buy rating and issued a $27.00 price target on shares of Spero Therapeutics in a report on Thursday, May 9th. Finally, Zacks Investment Research raised DLH from a sell rating to a hold rating in a report on Tuesday, July 9th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Aimmune Therapeutics presently has an average rating of Hold and a consensus price target of $41.43.

AIMT stock opened at $19.00 on Thursday. Aimmune Therapeutics has a twelve month low of $16.95 and a twelve month high of $36.12. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.65 and a current ratio of 7.65. The company’s 50-day moving average is $20.17.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.87) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.94) by $0.07. As a group, equities analysts forecast that Aimmune Therapeutics will post -3.77 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Cable Hill Partners LLC lifted its holdings in Aimmune Therapeutics by 81.7% in the 1st quarter. Cable Hill Partners LLC now owns 1,112 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 500 shares in the last quarter. Manchester Capital Management LLC purchased a new position in Aimmune Therapeutics in the 1st quarter worth approximately $27,000. Pearl River Capital LLC purchased a new position in Aimmune Therapeutics in the 1st quarter worth approximately $28,000. Marshall Wace North America L.P. bought a new stake in Aimmune Therapeutics in the 1st quarter worth approximately $32,000. Finally, Advisor Group Inc. increased its stake in Aimmune Therapeutics by 84.6% in the 4th quarter. Advisor Group Inc. now owns 1,737 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 796 shares during the last quarter. 76.12% of the stock is currently owned by institutional investors.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

Read More: What is a Futures Contract?

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.